The NCCN 9th Annual Congress: Hematologic Malignancies™ took place September 19 – 20, 2014, in New York, NY.

Overview:
Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Intended Audience:
These activities are designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Accreditation:
These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. Complete accreditation details are provided at the beginning of the individual activities.

Fee Information:
There is no fee for these educational activities.

Supporters:
Supported by educational grants from Foundation Medicine, Inc.; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Pharmacyclics, Inc. and Janssen Biotech, Inc.; and Takeda Oncology

Click the title of an activity below to proceed.